Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 MY3: Transcriptional Profiling of Canine Soft Tissue Sarcoma”
Research Update CHF 02780 MY3: Bladder Carcinogen Exposures in Pet Dogs
Bladder cancer case recruitment has been steady through our alliance with Antech, which is attaching our study flyer to all BRAF urine tests that are positive for bladder cancer. We are now enrolling 2-3 dogs with bladder cancer per month. We also have a list of possible matched controls through our expanded outreach through Facebook. We have recorded questionnaire data encoded for all dog kits that have been returned to us. Continue reading “Research Update CHF 02780 MY3: Bladder Carcinogen Exposures in Pet Dogs”
Research Update Final 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma
Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Continue reading “Research Update Final 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma”
Research Update CHF 02783 EY2: Transcriptional Profiling of Canine Soft Tissue Sarcoma
Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 EY2: Transcriptional Profiling of Canine Soft Tissue Sarcoma”
Research Update CHF 02534 MY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
We opened the trial on July 1, 2019. As of June 27, 2021, we have enrolled 18 dogs in the study and no dose limiting toxicities within the initial 21-day assessment period have been observed. Based on these results, we are continuing to enroll dogs at the highest dose of propranolol (1.3 mg/kg) being tested. Continue reading “Research Update CHF 02534 MY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”
Research Update CHF 02806-MOU MY2: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up
The goal of this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of the disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. Continue reading “Research Update CHF 02806-MOU MY2: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”
Research Update CHF 02783 EY1: Transcriptional Profiling of Canine Soft Tissue Sarcoma
Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 EY1: Transcriptional Profiling of Canine Soft Tissue Sarcoma”
Research Update CHF 02780 EY1: Bladder Carcinogen Exposures in Pet Dogs
Right after our AKC Canine Health Foundation grant funding started in March 2020, our lab was closed for 3 months due to COVD-19 and has since been limited to 50% occupancy. In addition, our teaching hospital has had limited appointments since March 2020.
We finished a few validation experiments on our DNA damage assays that were needed before recruitment, and we have started recruiting dogs with bladder cancer and matched controls. We enrolled our first two new cases and two controls this month. Continue reading “Research Update CHF 02780 EY1: Bladder Carcinogen Exposures in Pet Dogs”
Research Update CHF 02758 EY1: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms
Thank you for supporting our project titled “Optical coherence tomography for margin evaluation of skin and subcutaneous neoplasms”. This project is investigating an emerging diagnostic imaging tool, optical coherence tomography that uses light waves to generate real time high-resolution images of tissues for detection of residual cancer cells immediately following surgical removal. Our team involves collaboration between veterinary medicine and pathology at the Ohio State University. We have had excellent progress in our patient enrollment, we completed enrollment of the 80 cases planned already! Continue reading “Research Update CHF 02758 EY1: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms”
Research Update CHF 02502 EY3: Precision Medicine for Canine Lymphoma
We have successfully developed a canine cancer gene panel that we have called the Canine Oncopanel, using cutting-edge, next-generation sequencing technology (NGS). The Canine Oncopanel allows sequencing of 283 cancer-related genes and detection of mutations within these genes that may drive the tumor cells to proliferate and survive. The canine oncopanel sequences a total target region that equates to ~3% of the canine genome. Analyzing the genomic composition of this broad target region allows evaluation of common genomic alterations that can lead to the development of cancer. The Canine Oncopanel is suitable to map mutation profiles and identify driver mechanisms in both common and rare canine cancers to provide a better understanding of the tumor genome and its biology.
Continue reading “Research Update CHF 02502 EY3: Precision Medicine for Canine Lymphoma”